Bone Biologics Corporation is a developer of orthobiologic products for spine fusion markets. It is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. It is a medical device company that is focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with demineralized bone matrix (DBM), is an osteopromotive recombinant protein that provides target specific control over bone regeneration. Its platform technology is its NELL-1, a proprietary skeletal specific growth factor which is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
Ticker SymbolBBLG
Company nameBone Biologics Corp
IPO dateNov 27, 2015
CEOMr. Jeffrey Frelick
Number of employees2
Security typeOrdinary Share
Fiscal year-endNov 27
Address2 Burlington Woods Dr Ste 100
CityBURLINGTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code01803-4551
Phone17815524452
Websitehttps://www.bonebiologics.com/
Ticker SymbolBBLG
IPO dateNov 27, 2015
CEOMr. Jeffrey Frelick
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data